Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) have received a consensus recommendation of “Buy” from the twenty-six brokerages that are covering the firm. Three research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $133.78.

Several research firms recently commented on ZBH. Leerink Swann restated an “outperform” rating and issued a $136.00 price target (down previously from $150.00) on shares of Zimmer Biomet Holdings in a report on Tuesday, November 1st. Citigroup Inc. raised shares of Zimmer Biomet Holdings from a “sell” rating to a “neutral” rating in a research report on Tuesday. SunTrust Banks Inc. began coverage on shares of Zimmer Biomet Holdings in a research report on Thursday, August 11th. They issued a “buy” rating and a $155.00 price objective for the company. RBC Capital Markets reaffirmed an “outperform” rating and issued a $130.00 price objective (down previously from $143.00) on shares of Zimmer Biomet Holdings in a research report on Tuesday, November 1st. Finally, Jefferies Group lowered their price objective on shares of Zimmer Biomet Holdings from $150.00 to $129.00 and set a “buy” rating for the company in a research report on Tuesday, November 1st.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is the propert of of Daily Political. If you are viewing this news story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this news story can be viewed at http://www.dailypolitical.com/2016/11/29/zimmer-biomet-holdings-inc-zbh-given-consensus-recommendation-of-buy-by-brokerages.html.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 103.40 on Friday. Zimmer Biomet Holdings has a one year low of $88.27 and a one year high of $133.21. The firm has a market capitalization of $20.71 billion, a PE ratio of 57.89 and a beta of 1.28. The stock has a 50 day moving average of $112.33 and a 200-day moving average of $121.63.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Monday, October 31st. The company reported $1.79 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.79. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. The firm had revenue of $1.83 billion for the quarter, compared to analyst estimates of $950.20 million. During the same quarter last year, the firm posted $1.64 earnings per share. Zimmer Biomet Holdings’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, equities analysts predict that Zimmer Biomet Holdings will post $7.92 EPS for the current year.

In related news, insider Daniel E. Williamson sold 2,716 shares of Zimmer Biomet Holdings stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $129.96, for a total transaction of $352,971.36. Following the sale, the insider now directly owns 2,000 shares in the company, valued at $259,920. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.22% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Liberty Capital Management Inc. bought a new stake in shares of Zimmer Biomet Holdings during the third quarter worth $108,000. Tower Research Capital LLC TRC raised its position in Zimmer Biomet Holdings by 205.3% in the second quarter. Tower Research Capital LLC TRC now owns 916 shares of the company’s stock worth $110,000 after buying an additional 616 shares during the last quarter. NEXT Financial Group Inc raised its position in Zimmer Biomet Holdings by 64.5% in the third quarter. NEXT Financial Group Inc now owns 913 shares of the company’s stock worth $119,000 after buying an additional 358 shares during the last quarter. Global X Management Co. LLC raised its position in Zimmer Biomet Holdings by 238.4% in the second quarter. Global X Management Co. LLC now owns 1,032 shares of the company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 964 shares of the company’s stock worth $125,000 after buying an additional 5 shares during the last quarter. Institutional investors and hedge funds own 85.05% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.